Speakers
- Dean Banks
-
- Vice President
Highland Capital Partners - Dean Banks is a Vice President at Highland Capital Partners focusing on healthcare investments and specializing in medical devices and diagnostics. Prior to joining Highland, Dean was an Associate Principal at Cytyc Corporation, a leading diagnostic and medical device company dedicated to the improvement of women's health. Before joining Cytyc, Dean worked for Cambridge Endoscopic Devices as a VP of Business Development and Marketing. Dean began his business career at Ethicon Endo-Surgery, a J&J company marketing advanced medical devices for minimally invasive surgical procedures. During his five-year tenure, he held a variety of positions in management, sales and professional education. Dean received his B.A from Miami University and his M.B.A from Harvard Business School.
- Ramsay Battin
-
- Director Venture Capital – Atlanta
Arcapita Ventures - Ramsay Battin is a Director with Arcapita Ventures. Prior to joining Arcapita, Ramsay was a Partner with Southeastern Technology Fund, a $120 million early stage venture capital firm, where he focused on healthcare technology and enterprise and infrastructure software. He has also served in the Corporate Finance Departments at Lehman Brothers and Robinson-Humphrey in their private equity and healthcare coverage groups in New York, London and Atlanta. Ramsay currently serves on the Board of Directors of Prenova and Fidelis SeniorCare, and previously served as a member of the Board of Directors of Best Doctors, RTO Software, Seventh Wave and SPI Dynamics. Ramsay received his Bachelor of Arts degree from Princeton University and holds his MBA from the Harvard Business School.
- Maureen Bennett
-
- Partner, San Francisco
Squire Sanders -
Maureen Bennett is a partner in the firm’s corporate and environmental practice groups.
She assists clients in a wide variety of international mergers and acquisitions and commercial transactions. She frequently works with non-US-based companies investing in the United States and with US-based companies investing abroad.
Ms. Bennett has represented both private and public pharmaceutical and life sciences companies in connection with the negotiation of domestic and international clinical trial site agreements, CRO agreements and related consulting agreements. She also assists pharmaceutical and agricultural chemical companies in connection with cross-boundary acquisition and investment transactions, as well as product supply, manufacturing and development agreements.
Ms. Bennett has presented on the topic of clinical trial disclosure liability before the International BioMed Society (2004), the Arizona BioIndustry Association, the Massachusetts BioTechnology Council and the New England Chapter of Clinical Research Professionals (2005). She has also presented on the topic of managing global clinical trials before the BayBio Exposition (2005).
Ms. Bennett also assists clients in a wide range of financing, merger and acquisition and other transactional arrangements, with an emphasis on environmental issues. She has assisted lenders, developers, buyers and investors in assessing and quantifying environmental risks, structuring appropriate risk allocation arrangements and determining permit requirements involving commercial properties and manufacturing and cogeneration facilities.
- Terence S. Bentley
-
- Corporate Development / M&A
Teleflex Corporation - Terence Bentley is Senior Director, Corporate Development at Teleflex,
a $2.5B diversified medical device and equipment company. In 2007,
he sold businesses with revenues over $1B in cross border transactions
for Teleflex. He is focused on acquiring technology companies in
the medical equipment market.
With 15 years in M&A, he has closed over 40 transactions with individual values up to $3B for Teleflex, ADP, Lucent and Siemens in aerospace, manufacturing, applications services, internet software, fiber optic products, network equipment, LAN switching systems and semiconductors.
Prior to specializing in M&A, he was a product manager, delivering 25+ products to market in Local Area Networks, data communications and cable television network systems. He has an MBA in finance. Email: tbentley@teleflex.com.
- David Biondo
-
- Senior VP Investment Banking
Viscogliosi & Company Inc. - David I. Biondo is a Senior Vice President of Investment Banking
at Viscogliosi & Co., Inc. a FINRA registered broker dealer.
Viscogliosi & Company focuses on providing financing and investment
banking activities to companies in the orthopedic medical technology
industry. Prior to joining Viscogliosi & Co., David was Director
of Corporate Finance at Paradigm Spine, LLC (a Viscogliosi Brothers,
LLC portfolio company), a leading spine non-fusion medical device
company. Prior to joining Paradigm Spine, David worked for
Viscogliosi Brothers, LLC, a merchant bank focused on developing
life-changing orthopedic technologies, as a corporate finance associate.
Before joining Viscogliosi Brothers, David worked for Distribution Services,
Inc., a regional logistics service provider, as General Manager for the
Midwest region. David was also an orthopedic research associate
at Rodman & Renshaw, Inc. in 1997, and interned for Anthony Viscogliosi
at Martin Simpson & Co in 1993. David received his B.A. in Economics
from the University of Michigan.
- Kevin Buckley
-
- Managing Director
BioTactica - Kevin Buckley is a partner in the Intellectual Property group at
Spencer Fane Britt & Browne LLP. His practice focuses on life sciences
patent and transactional legal issues, including technology transfer and
licensing, pharmaceutical life-cycle management, institutional collaborations,
and venture finance. He also counsels on regulatory matters pending before
the FDA, USDA and EPA. Previously, Mr. Buckley was the founder and President
of Biotactica, LLC where he counseled international clients in acquiring,
protecting and commercializing biotechnologies and pharmaceutical technologies
in the U.S. and abroad.
He received a J.D. from the University of Pittsburgh where he was the Editor-in-Chief of The Pittsburgh Journal of Technology Law & Policy, and received a B.S. in Biochemistry from the University of California, San Diego where he was a Research Scholar.
- Len Cosentino
-
- Vice President and General Counsel
NDI Medical, Inc. -
Len Cosentino serves as Vice President, Business Development and General Counsel to NDI Medical, a neurostimulation medical device company based in Cleveland, Ohio, and has a broad range of experience assisting early stage technology companies, public and private companies, venture capital firms and entrepreneurs with merger, acquisition, joint venture, finance and investment transactions. Before joining the NDI Medical in 2006, Mr. Cosentino provided transactional and general legal services to NDI Medical as a partner in the Cleveland, Ohio based law firm of McDonald Hopkins LLC where he continues to be Of Counsel. A 1987 graduate of Case Western Reserve University School of Law (magna cum laude, Order of the Coif), Mr. Cosentino began his legal career at the law firm of Jones Day in Cleveland, Ohio. From 1993 to 2000, Mr. Cosentino served as Vice President and General Counsel of a privately-owned company in the insurance industry where he served both as legal counsel and in operations management.
- Peter Csikos
-
- Business Development Director
ValDean Innovation Zrt -
Peter Csikos: Business Development Director at ValDeal Innovation Zrt.,
responsible for the development and commercialization of the projects
managed by ValDeal, the first Central European Technology Accelerator.
Previously he worked as the Head of Technology Transfer and Innovation at
Eötvös Loránd University (Budapest, Hungary), and during this period he
established the technology transfer system and functions of the institute
and also strengthened the university’s connections with industries.
He also gained experience in strategic consulting, and earlier for four years,
he acted as a business development associate, later as a business development
manager of SOLVO Biotechnology, a startup company active in the field
of drug transporters and Drug Metabolism / Pharmakokinetics research.
At present he still works as an external consultant for startup companies
dealing with innovation and technology transfer and an external lecturer
of Central European University. Graduated as a Master of Laws,
later obtained MSc. Econ and MBA degrees.
- Michael Goldberg
-
- Managing Partner
Bridge Investment Fund L.P. -
Michael Goldberg is a Managing Partner of the Bridge Investment
Fund LP. Bridge, which has offices in Cleveland and Tel Aviv,
is a venture capital fund focused on investing in Israeli medical
device companies that have synergies with the leading health care
industries and institutions in Northeast Ohio. Previously,
Michael was the Director of International Business Development
for America Online, Inc. responsible for structuring and negotiating
international joint venture partnerships in Asia. Earlier
in his career, Michael spent several years in South Africa working
for the National Democratic Institute for International Affairs (NDI)
designing and implementing voter education programs for South Africa’s
historic first democratic election in 1994. Michael also
founded WorldTeach’s pilot program to send American teachers to
rural black schools in South Africa and served as the first
volunteer teacher in the program.
Michael was a term member of the Council on Foreign Relations and a German Marshall Fund Marshall Memorial Fellow. He was a member of the Leadership Cleveland Class of 2007 and serves on the Funders Committee for the Fund for Our Economic Future focused on promoting economic development in Northeast Ohio. He also serves on the boards of Citizens Academy, the Cleveland Leadership Center, Summer on the Cuyahoga and is the co-chairman of the Cleveland chapter of the National Security Network. Michael is also a member of the International Advisory Board of the Hartog School of Government and Policy at Tel Aviv University.
A native of Cleveland, Ohio, Michael earned a BA from the Woodrow Wilson School of Public and International Affairs at Princeton University, MA in International Relations from the School of Advanced International Studies (SAIS) at Johns Hopkins University and MBA from The Wharton School at the University of Pennsylvania.
- Neil Goldsmith
-
- Managing Director & CEO
Evolva SA -
20 year track record in building biotech companies from foundation to exit.
Of previous companies 5 achieved stock market listings, 1 a successful trade sale,
1 remains private and 3 failed. Previous companies include: TopoTarget,
Personal Chemistry, Phytera, PNAD, BIAcore, Quadrant. BA Hons (1st class)
in Zoology from Balliol College, University of Oxford. Co-founder.
- Kent Gossett
-
- Principal
SR One -
Kent joined SR One in 2003 after three years at GSK Ventures. He is
a member of the Board of Directors of Algeta ASA, Protez Pharmaceuticals,
CalciMedica, and Resistentia Pharmaceuticals AB.
He was previously Director of Alere Medical and Observer for TorreyPines Therapeutics and Morphotek Inc. Kent has held positions in Scientific Licensing (1999-2000) Clinical Pathology and Safety Pharmacology (1993-1999) at SmithKline Beecham Pharmaceuticals, Assistant Research Director of Clinical Pathology at Sterling Winthrop Pharmaceuticals (1989-1992) and Assistant / Associate Professor of Veterinary Clinical Pathology at Louisiana State University.
Kent received his DVM and MS from Purdue University, his PhD in Veterinary Clinical Pathology from Louisiana State University, is a Diplomat of the American College of Veterinary Pathologists, and received his MBA from the Wharton School of the University of Pennsylvania.
- Tim Hansen
-
- Director
JVax Investment Group, LLC -
Tim Hansen is a Director of JVax Investment Group, LLC focusing on later-stage
medical devices and diagnostics with an emphasis on early International
distribution. Prior to joining JVax in 2008 he was CEO of Imaging
Diagnostic Systems, Inc. a development stage public company specializing
in breast cancer optical imaging. Prior to IDSI, he was the senior
executive of Inovision a private company devoted to radiation test and
measurement instruments and services; he was instrumental in selling the
company to Mallinckrodt, Syncor, Cardinal Health and Danaher. Earlier,
Tim was President of Picker Medical System, a multimodality imaging company
of international scope. While at Picker he acquired numerous imaging
technology and service related businesses and formed many joint development
programs in his 20 year tenure. He also held senior sales and marketing
roles at General Electric Medical Systems and Smith Kline Instruments.
Tim has a B.S. in Economics from the University of Wisconsin.
- Avshalom Horan
-
- Managing Partner
Bridge Investment Fund L.P. - Dr. Avshalom Horan is a Managing Partner at the Bridge Investment Fund - a VC
based in Cleveland and Tel Aviv, focused on investing in Israeli early stage
med-tech companies that are getting ready to launch their US operation.
Horan has an extensive background in seed investment and management of technology
companies through their early stages. During his service in the Israeli
Military Intelligence, he headed a special department overseeing the development
of major projects involving state of the art technologies. Horan was the
VP of a technology subsidiary of the Bank Leumi Investment Group and has served
on the board of directors of several private and public Israeli companies.
He founded and directed a technology incubator in Israel where several startup
companies were seed funded. Horan is the chairman of Simbionix, a company
that was started in that incubator and has later co-located in Cleveland.
Simbionix is a lead developer of surgical simulation systems with over $10 million
in revenue in 2007. Horan is a venture partner with Tenne, an Israeli Private
Equity Fund. He holds a Ph.D. in Engineering-Economic Systems from Stanford
University, and is a decorated Colonel (res.) in the Israeli Defense Forces (IDF).
- Andrew Jay
-
- Managing Partner, Medical Solutions Fund
Siemens Venture Capital, Inc. - Dr. Andrew Jay is Head of the Medical Fund at Siemens Venture Capital.
He currently is on the Board of Directors of Molecular Insight Pharmaceuticals,
RadPharm, U-Systems, and Vasomed. He is also involved with MDdatacor,
Sequenom and Cylex. Dr. Jay previously was a medical technology analyst
at Wachovia Securities and Deutsche Bank. He was instrumental in raising
over $2 billion in equity capital, publishing over 10,000 pages of research
and bringing 30 medical technology companies public. He was frequently
interviewed in the financial trade press including the Wall Street Journal,
CNN and MSNBC. He has a Bachelor of Science from Rensselaer Polytechnic
Institute, a DMD from the University of Pennsylvania and an MBA from the Kellogg
School at Northwestern.
- Carol Kovac
-
- Partner
Burrill & Company -
Dr. Kovac joined Burrill & Company after retiring from IBM, where she was responsible for the strategic direction of IBM's global healthcare and life sciences business. She led a team in developing the latest information technology solutions and services, establishing partnerships and overseeing IBM investment within the healthcare, pharmaceutical and life sciences markets. In more than 20 years at IBM, Dr. Kovac held a number of executive management positions, including vice president at IBM Research, where she was instrumental in launching the Computational Biology Center and the massive Blue Gene supercomputer project. Starting with only two employees as an emerging business unit in the year 2000, Dr. Kovac successfully grew IBM's life sciences business unit into a multi-billion dollar business, and one of IBM's most successful ventures to date with more than 1500 employees worldwide. Her main focus at Burrill is developing and executing investment strategies for leading edge technologies that are contributing to the transformation of medicine and healthcare including: personalized medicine, the use of IT in healthcare, stem cell research, medical devices and diagnostics, and bio-nanotechnology. In addition, she will work as part of the Burrill International Group team building the company's life science focus on emerging economies such as China, India, Malaysia and the Middle East.
- Frank Kung
-
- Managing Partner
Vivo Ventures -
Frank Kung is a founder and managing member of the Palo Alto, CA based
Vivo Ventures, LLC, a venture capital management firm established in 1996,
currently with more than $650MM under management. He joined Cetus
Corporation in 1979, co-founded Cetus Immune Corporation in 1981.
In 1984 he co-founded Genelabs Technologies, Inc. where he served as Chairman
and CEO until 1995. He brought the company public in 1991, and built it
to a 175 employee international biotech company. Dr. Kung received his
B.S. in chemistry from the National Tsing Hua University in Taiwan, his Ph.D.
in molecular biology and MBA from the University of California, Berkeley.
He currently serves on the board of directors of a number of biotechnology companies.
- Vivian Lee
-
- Managing Director
Aqua Partners LLC -
With Aqua Partners, a strategic and financial advisory firm she founded
in 1983, Vivian has worked with numerous companies, investment firms,
universities and government agencies worldwide. She served as a
reviewer to the US Congressional Office of Technology Assessment in its
first report on commercial biotechnology, and her analyses of biotechnology
industry and financing trends have been published by Bio/Technology,
BioIndustry (Japan), In Vivo, Biotechnology News, Decision Resources
and Drug & Market Development. As a venture partner managing
International Biomedicine Fund, she served as a director on the board
of Innodia, and as an observer on the board of Syntonix Pharmaceuticals.
Vivian began her career as a venture analyst at WR Grace & Co.
- Allison K. Nelson
-
-
Vice-Consul, Research & Development Officer
UK Trade & Investment -
Allison Nelson is Research and Development Officer in UK
Trade & Investment (UKTI) at the British Consulate-General
in Chicago. UKTI is the Government organisation that supports
companies in the UK doing business internationally and overseas
enterprises seeking to set up or expand in the UK. Highlighting
the UK's scientific excellence, Ms. Nelson works with government,
industry, and academia to develop scientific collaborations and
partnerships between researchers in the UK and their counterparts
in the US. Prior to joining UKTI, Ms. Nelson worked for several
years in business development and scientific due diligence with
MDB Capital Group, a boutique investment bank focused on small-
and micro-cap technology companies. At MDB, she worked to develop
a business intelligence tool to enable the investment community
to use intellectual property to evaluate companies and emerging
technologies. She also spent several years as a research scientist
for Lumera Corp, where she was one of the founding employees,
designing and synthesizing electro-optic molecules for use in
fiber-optic communications. Ms. Nelson received her MS in Organic
Chemistry from the University of Southern California, with an
emphasis on the synthesis, physical properties, and technical
applications of siloxane polymers. She earned her BS in Organic
Chemistry from the University of Washington, with an emphasis
on immunological biochemistry and protein chemistry.
- Jean-Pierre Novak
-
- Vice President
France Agency -
Vice-President at the Invest in France Agency North America since September 2006,
Jean-Pierre Novak is responsible for following and acquiring potential investment
from companies based in Michigan and the areas of Cleveland and Columbus in Ohio.
Jean-Pierre previously held the position of economic attaché at the French Embassy
in Berlin (Germany) and commercial attaché at the French Trade Commission in Chicago
and Cologne (Germany). Jean-Pierre has an engineering degree and also a Master’s
degree from the ESSEC business school in Paris.
- Mark Maciejewski
-
- Senior VP International Investment
NTEC, Kuwait -
Mark Maciejewski is currently the Chief Executive Officer of RegenRX,
a company focused on developing innovative regenerative therapies for
cardiovascular disease. Prior to this Mr. Maciejewski was Founder,
Director, President, and Chief Executive Officer of Symphony Medical, Inc.
Mr. Maciejewski also held the position of Managing Director, Healthcare,
for Tyco Ventures, a corporate sponsored venture capital firm of Tyco
International Ltd. Prior to joining Tyco Ventures, Mr. Maciejewski was
the founder of Ascent Private Equity, a medical technology focused venture
capital firm located in New York City. Mr. Maciejewski has 21 years
experience in the medical technology industry, including launching a variety of
medical device start-ups such as Angioguard (acquired by Johnson & Johnson), Devax,
Inc., American Medical Systems, InStent, Palamar Medical and Angiosonics.
His medical technology expertise is enhanced by his experience in worldwide
sales and marketing management and product and business development.
He received his B.S. from the University of Dayton, and an MBA from St. Thomas University in St. Paul.
- Ting Pau Oei
-
- Partner
L Capital - Ting Pau Oei is a Partner of L Capital Partners SBIC, LLP and leads the firm’s efforts
in healthcare investments. Mr. Oei joined L Capital Partners in 2004 after a
distinguished 22 year career at Johnson & Johnson. Mr. Oei has been in the venture
capital business for over 15 years, invested in over 55 venture backed private healthcare
companies. Mr. Oei has made investments in a broad range of companies including
early-stage startups to developmental/growth stage companies to investments in public
companies. Currently, Mr. Oei is on the board of directors of Protez Pharmaceuticals,
Inc., CeNeRx BioPharma, Inc., IntraPace Inc., ProRhythm, Inc. and Locus Pharmaceuticals,
Inc. Mr. Oei received his undergraduate degree from Union College (N.Y.) and MBA
from Columbia Business School.
- Jayson D. Pankin
-
- New Venture Creation Specialist
Delphi Corporation - Jayson leads Delphi Technologies, Inc.’s commercialization activities targeting
spin-outs of potential “game changing technologies” into start-up companies.
This includes creating internal incubators and external ventures, such as the spinoffs
of SpaceForm, Inc. to commercialize a revolutionary metal welding technology, and
Monarch Antenna, to bring to market an advanced reception system applicable to next
generation consumer and military wireless devices. Both DTI and its spinouts
have received significant awards and recognition from industry groups and the trade
media. Jayson is developing a pipeline of disruptive technologies as candidates
for future spinout, including the smart antennas, infrared sensors, nano materials,
hydrogen generation and storage and application software innovations.
For over twenty-five years, Jayson has been a venture partner specializing in early stage and turnaround situations. He has started and participated in new ventures in a variety of industries: biotechnology, material sciences, retail, insurance, software, manufacturing and packaging. He has worked with numerous universities and Fortune 1,000 companies to acquire emerging technologies and form commercialization partnerships to grow new products and companies. He was a founder of Titan Auto, Inc., one of the largest insurance companies in Michigan and has advanced the commercialization of artificial blood and biological therapies for cancer and other serious illnesses. He started a non-profit foundation in Russia that used the broadcast media to disseminate pro-democracy motion pictures throughout the former Soviet Union. He earned his BBA in Accounting and MBA in International Business at the George Washington University.
- Leon A. Polott
-
- Founder and President
5iTech, LLC - Leon A. Polott is the founder and President of 5iTech, LLC a technology
commercialization company working to bring cutting edge high technologies
developed by former Soviet Scientists to US commercial and capital markets.
The company draws on Leon’s unique access to high technology from abroad, his
entrepreneurial skills and proven ability to effectively transform intellectual
property into viable US start ups.
Mr. Polott is Managing Director of Parus Fund I, an early stage venture fund, and of Pittsford Ventures V, a BRIC fund. He is a Director of Aria Analytics, Oculatek and Sterionics. By appointment of the US Department of Commerce, he serves on the US-Russia Innovation Council on High Technology.
For a dozen years, prior to establishing 5iTech, Mr. Polott practiced law with several prominent US law firms in California and Ohio. He served as the Chair of the International Law Section of the Cleveland Bar Association from 1999-2001.
A first generation immigrant to the United States, Leon is fluent in Russian and holds a BA with Honors in Government from Oberlin College and a JD from The University of Texas School of Law.
- Sanuj Ravindran
-
- Principal
Radius Ventures - Sanuj K. Ravindran, M.D. is a Principal of Radius Ventures. Prior to joining Radius in February 2007, Sanuj was a Director at Burrill & Company, a San Francisco based life science venture capital firm. While with Burrill, he served as a board observer to diaDexus and Proventys, and played an active role in several other investments, including Endocyte, Neosil, Cardiokine and Arete Therapeutics. Previously, Sanuj worked in the Healthcare Investment Banking Group at Merrill Lynch. He is Board Certified in Internal Medicine and served as a National Cancer Institute Research Fellow at Memorial Sloan Kettering Cancer Center. He is also a member of the Kauffman Fellows Program. Sanuj received a B.A. with Honors from Northwestern University, an M.D. from Jefferson Medical College, and an M.B.A from The Kellogg School of Management, where he was a Rothschild Scholar.
- Bruce Roberts
-
- Co Founder & Managing Director
Roberts Mitani - Bruce Roberts is a co-founder and Managing Director of Roberts Mitani, a New-York based investment bank, holds 20 years of global finance, private equity, business development, and law experience, with a focus on the healthcare and consumer sectors. He is a member of the Investment Committee of TTC-RMA Venture Partners, LLC and a board member of Pinyons Medical Technology, a cardiovascular tools company. His past directorships also include Endologix, a U.S. medical device company, Devax, a U.S. coronary stent company, and Global Biomedical Partners AG, a Swiss based biotechnology focused private equity fund management company. Bruce received a Bachelor of Arts in History and Government from Harvard College, summa cum laude, and a J.D. from Harvard Law School. He has also been a lecturer on Private Equity for the Executive MBA program of the NYU Stern School of Business.
- Charles E. Schneider
-
- Vice President, Reimbursement
Musculoskeletal Clinical Regulatory Advisers, LLC - Mr. Schneider is responsible for assisting MCRA’s clients in the preparation
of coding applications, creating reimbursement pathways, preparing submissions
for use by commercial carriers (TriCare, Medicare, and fiscal intermediaries),
and supporting national coverage determinations by CMS.
Mr. Schneider has held key positions with large and regional insurance carriers (Prudential, Blue Shield, Monarch) and the medical device community. Furthermore, Mr. Schneider served as the former CEO of Provider Solutions, LLC, a diversified healthcare management consulting group. Mr. Schneider was an executive of Capital Claims Acquisition of America, a revenue cycle management consulting and patient account management firm representing providers throughout the U.S.
Mr. Schneider has been an active participant within AdvaMed’s Payment & Policy Work Group as well as other national and regional trade organizations. Mr. Schneider has been highly effective in working with commercial carriers, technology assessment and value analysis committees. Furthermore, Mr. Schneider has authored numerous publications including reimbursement instructional guides; pre-paid healthcare and finance solutions; revenue cycle management; as well as design, certification and management of Centers of Excellence.
Mr. Schneider graduated from the University of Southern California with a Bachelor Degree in Political Science.
- Sanjay Sehgal
-
- Managing Partner & CEO
East West Capital Partners Pty. Ltd. -
Sanjay Sehgal is a founder and Managing Partner & CEO of East West Capital Partners, a healthcare-focused private equity firm based out of Singapore and Bangalore. Prior to EWCP, Sanjay was a Partner and member of the investment committee at Symphony Capital Partners (Asia) (f.k.a Schroder Capital Partners) focused doing development capital and buy-outs throughout the Asia-Pacific region. Prior to joining SCP in 1994, Sanjay was a Manager in the Boston office of LEK Consulting, an international strategy consulting firm. Sanjay has a Bachelor of Technology degree in Electrical Engineering from the Indian Institute of Technology, an MSc. in Electrical Engineering from Columbia University, New York and an MBA, with distinction, in finance and multinational management from The Wharton School of the University of Pennsylvania.
- Baiju R. Shah
-
- President
BioEnterprise Corporation - Baiju R. Shah is President and CEO of BioEnterprise, a partnership of Case Western, Cleveland Clinic, Summa Health, and University Hospitals. BioEnterprise is a business acceleration initiative to support the growth of bioscience companies. Since 2002, it has helped more than 60 Cleveland companies that have collectively attracted more than $600 million in new funding. Prior to BioEnterprise, Shah was with McKinsey & Company, where he played a leading role in the Growth and Business Building practice. In the community, Shah serves on Boards of The Saint Luke’s Foundation, Great Lakes Science Center, Yale Alumni Association, NorTech, and Summer on the Cuyahoga, and also the Governor’s Workforce Policy Board and Strategic Development Advisory Board. Shah received a J.D. from Harvard and his B.A. from Yale.
- Glenn Stiegman
-
- Vice President, Regulatory Affairs
Musculoskeletal Clinical Regulatory Advisers, LLC - Mr. Stiegman leads MCRA’s submission process, regulatory strategy,
analysis and development: from pre-clinical testing, to FDA submissions,
to market approval and post commercialization.
Prior to joining MCRA, Mr. Stiegman served as the Chief of the Orthopedic Devices Branch for US Food and Drug Administration. As Branch Chief, he managed a team of scientists, clinicians, and engineers in the regulation of all orthopedic devices marketed in the United States. Additionally, Mr. Stiegman was responsible for overseeing all FDA guidance documents and policy determinations for orthopedic devices marketed in the US. Furthermore, he assisted in and oversaw all integrity, compliance, and monitoring issues regarding the orthopedic industry in collaboration with the Office of Compliance.
Mr. Stiegman was also a member of Orthopedic Device Forum and Orthopedic Surgical Manufacturer Association. Mr. Stiegman pursued reclassifying several types of orthopedic devices, developing guidance documents on state-of-the-art orthopedic devices, and educating and assisting the orthopedic community in the regulatory strategies.
Mr. Stiegman received his Bachelor in Science at Tulane University in Biomedical Engineering and his Master in Science at Clemson University in Bioengineering with a focus on biomaterials and biomechanics.
- Dr. Anthony Sun
-
- Principal
Aisling Capital -
Dr. Sun joined Fund I in 2001-2002 and currently serves as a Principal.
Previously, Dr. Sun was an entrepreneur co-founding a disease management
company and an Adjunct Instructor of Medicine at the Hospital of the University of
Pennsylvania. Dr. Sun currently serves as a director of CeNeRx BioPharma, Inc.,
Dynova Laboratories, Inc., HerbalScience, Inc., and Paratek Pharmaceuticals, Inc.
Previously, he served on the board of MAP Pharmaceuticals, Inc. ("MAPP": NASDAQ).
Dr. Sun received his B.S. in Electrical Engineering from Cornell University and his
M.D. from Temple University School of Medicine with A.O.A. honors. In addition,
he is a Board Certified Internist and has an M.B.A. from The Wharton School
at the University of Pennsylvania.
- David Tharp
-
-
Vice Consul and USA Sector Lead, Biotechnology & Pharmaceuticals
UK Trade & Investment - David Tharp is a Vice Consul at the British Consulate General and
Sector Lead for the Biotechnology & Pharmaceuticals Industry in
the US market for UK Trade & Investment (UKTI). Mr. Tharp
leads a team of approximately 20 officers and business development
associates in the US focused on advising UK companies on their market
entry strategy as well as the expansion plans of larger US companies
to the UK. This team is based at the eight British Consulates
across the US and the British Embassy in Washington D.C.
Prior to joining UKTI, Mr. Tharp was employed by Decision Resources, an international publishing and consulting firm evaluating world-wide markets and emerging technologies in the biopharmaceutical industry where he co-authored reports focusing on the importance of biological pathways in market segmentation and analysis.
Mr. Tharp earned a BSc. in biology with a concentration in genetics from the University of Massachusetts at Amherst and has contributed to several research projects in private and academic settings, including an appointment as visiting scientist at the Whitehead Institute/MIT Center for Genome Research and Massachusetts General Hospital in the field of psychiatric population genetics. He is currently pursuing a M.B.A. at the Saïd Business School at the University of Oxford.
- Gerald Turner
-
- General Partner
Seraphim Capital \ Focus Enterprises -
Gerald Turner is a Managing Director at Focus LLC, a leading middle market
investment bank, headquartered in Washington, D.C. with offices in Atlanta,
Chicago and San Francisco. Mr. Turner’s practice is trans-Atlantic
in scope. He is also a founder and Investment Director of Seraphim
Capital, a London, England, based early stage venture capital fund.
He is a founder of Atlantic BioBridge, a consultancy designed to deliver
services to build global life science businesses on both sides of the Atlantic.
He represents FOCUS on the Board of Advisors of the Business Growth Alliance,
a group of service providers to family owned businesses. He is a Member
of the British-North American Committee, a forum for business and academic
leaders from the United States, Canada and Britain. Mr. Turner was
educated at Oxford University, at the Wharton Graduate School of Business,
and at the Harvard Graduate School of Business.
- Anthony G. Viscogliosi
-
- Principal
Viscogliosi Bros., LLC - Mr. Viscogliosi founded Small Bone Innovations, Inc. (SBI) in 2004 and raised $42.2 million in 2005 – then the largest ever round of VC financing in orthopedics. SBI was recognized by Red Herring – in 2006 – as a Top 100 Technology Company in North America and – in 2007 – a Top 100 Global startup company – the only orthopedics company chosen. SBI was also honored by consulting firm, Frost & Sullivan, as 2007’s Entrepreneurial Company of the Year. In 1999, he co-founded Viscogliosi Bros. LLC a banking firm that has helped 170 companies, including SBi. Mr. Viscogliosi received an Honorary Degree of Doctor of Humane Letters-Honors Causa (D.H.L.) from the NY College of Podiatric Medicine, in 2007, and his B.S. in Economics from the University of Michigan in 1984.
- Marc R. Viscogliosi
-
- Principal
Viscogliosi Bros., LLC - Mr. Viscogliosi is a founder of the Company and has been its Chief Executive Officer and Chairman of the Board of Managers since August 2004. Prior to founding the Company, Mr. Viscogliosi was a co-founder and secretary of the Board of Directors of Spine Solutions, Inc. which was acquired by Synthes-Stratec in 2003. Prior to co-founding Spine Solutions, in 1999, Mr. Viscogliosi co-founded VB, a leading merchant bank and venture capital firm focused on the musculoskeletal/orthopedics industry. VB is the holder of the largest membership interest in the Company and owns 100% of the outstanding capital stock of the Placement Agent. Mr. Viscogliosi spent six years researching and banking musculoskeletal companies prior to co-founding VB. He was employed for four years as a musculoskeletal/orthopedic research associate, primarily working with his brother, Anthony. Mr. Viscogliosi was a research associate at Stifel, Nicolaus & Co., Inc., Rodman & Renshaw, Inc. and Commonwealth Associates. From 1992 to 1993, Mr. Viscogliosi worked as an intern at Martin Simpson & Co. and its successor firms. Mr. Viscogliosi has served on two boards of directors of musculoskeletal companies. Mr. Viscogliosi graduated from New York University in 1999 with a B.A. in Economics and Political Science.
- Dr. Garrett Vygantas
-
- Senior Associate
Burrill & Company - Dr. Garrett Vygantas joined Burrill & Company in 2006 as a Senior Associate
in the Venture Group and is involved in the sourcing and evaluating of new
investment opportunities across the life science spectrum. Dr. Vygantas
is also part of the Burrill International Group. He recently co-founded
and was interim CEO for NewBridge Pharmaceuticals, a Dubai-based specialty
pharmaceutical company commercializing innovative therapies to treat diseases
of increasing incidence (diabetes, obesity, cardiovascular and cancer) in the
Middle East, Africa, Turkey and Caspian regions. Before joining Burrill,
he was with Genentech’s Market Planning Group where he focused on the
commercialization and launch of Lucentis® (ranibizumab injection) for the treatment
of wet age-related macular degeneration. Prior to Genentech, Dr. Vygantas
worked with retinal specialists in Chicago where he consulted on a variety of
diabetes-related ophthalmic imaging projects. Dr. Vygantas previously
served as an Intern for Burrill & Company (Venture Group), Cowen (Healthcare
Investment Banking Group), and EntreMed (Business Development). Garrett
serves on the Board of Directors of NewBridge and is an observer on Proventys,
Efficas and TRF Pharma. Along with Dr. Zack Scott, he is a Co-Instructor
at UCSF’s Center for BioEntrepreneurship’s “Idea to IPO” curriculum and has
advised in the formation of numerous start-up biotech companies. Having
completed his Transitional Residency at the University of Pennsylvania,
Dr. Vygantas is a licensed and practicing physician. Dr. Vygantas holds
MD & MBA degrees from Georgetown University, as well as a B.S. in Biochemistry
from Boston College.
- Scott E. Weiner, MBA
-
- Principal
Pappas Ventures -
Scott joined Pappas Ventures in February 2006. Prior to that, he was an
investment manager and research analyst for Silverback Asset Management's life
sciences fund where he focused on healthcare securities investing. Before
joining Silverback, he spent three years at Chicago Growth Partners (formerly
William Blair Capital Partners), a private equity firm with approximately
$1 billion under management, where he was a Vice President focusing on
healthcare venture capital investments. Previously, he spent three
and a half years in investment banking at Lehman Brothers, where he worked
in the health care group in New York covering biotechnology and drug delivery,
the financial sponsors/leveraged finance group in London, and the media/telecom
group in Hong Kong. Scott also spent a year performing research on cell
apoptosis at the Duke University Levine Science Research Center.
Copyright © 2008 International Business Forum. All Rights Reserved.